The commercial potential for this technology was highlighted when Phylogica
entered into a US$142m deal with Genentech/Roche – our fifth partnership with
a major international pharmaceutical company. This collaboration is aimed at
using the Endosomal Escape Trap to discover novel intracellular drugs to treat
drug resistant superbugs.
It seems a little strange that they claim they can now scan pretty much any cell for cpp with endosomal escape, and yet in the months since this collaboration started nothing has been announced. I would have thought scanning a cell from the "superbug" and finding the peptide to penetrate it would be relatively easy if they can do what they claim.
PYC Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)